NCT03895567View on ClinicalTrials.gov

Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Healthy
Interventions
DRUG

A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)

"Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche)."

DRUG

B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)

"Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule"

DRUG

C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)

"Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet"

Trial Locations (1)

10400

Faculty of Tropical Medicine, Mahidol University, Bangkok

All Listed Sponsors
collaborator

Biopharma (Orofino Pharmaceuticals Group)

UNKNOWN

lead

University of Oxford

OTHER

NCT03895567 - Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection. | Biotech Hunter | Biotech Hunter